Physician profile
Mark Jaffe
NPI 1629089107
$6,126.75
in general payments reported to CMS, 2019-2025
32 companies · $803 in 2025
The $803 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $805 · 2020: $172 · 2021: $19.43 · 2022: $305 · 2023: $2,196 · 2024: $1,827 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,680 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,680.37 |
| Education | $144.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hill Dermaceuticals, INC. | $836.98 | 2023-2024 | Tolak |
| Galderma Laboratories, L.P. | $597.05 | 2019-2025 | Aklief, Oracea, Epsolay |
| Genzyme Corporation | $511.32 | 2020-2025 | |
| Janssen Biotech, INC. | $500.36 | 2019-2025 | Tremfya |
| Pfizer INC. | $384.81 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $355.79 | 2019-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $324.98 | 2023-2025 | Sotyktu |
| Abbvie INC. | $286.17 | 2022-2025 | |
| Amgen INC. | $260.04 | 2023-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $255.67 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $186.90 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $170.14 | 2019-2024 | Jublia, Arazlo, Duobrii |
| Incyte Corporation | $165.76 | 2022-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $143.23 | 2019-2023 | Dupixent |
| Dermira, INC. | $125.00 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $122.98 | 2023-2024 | Taltz, Olumiant |
| Mayne Pharma Commercial LLC | $119.13 | 2022-2023 | |
| Verrica Pharmaceuticals INC. | $99.16 | 2023-2024 | Ycanth |
| Dermavant Sciences, INC. | $92.26 | 2023-2024 | Vtama |
| Leo Pharma INC. | $92.20 | 2023-2024 | Adbry |
| Encore Dermatology INC. | $87.65 | 2019-2020 | |
| Ucb, INC. | $72.87 | 2024-2025 | Bimzelx |
| Organon LLC | $52.62 | 2023-2025 | Vtama, Hadlima |
| Biofrontera INC. | $52.27 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Almirall LLC | $49.87 | 2022-2023 | Seysara |
| Sebela Pharmaceuticals INC. | $43.99 | 2022-2023 | Naftin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.11 | 2024 | Spevigo |
| Mission Pharmacal Company | $31.22 | 2019 | |
| Botanix Sb INC | $20.34 | 2025 | Sofdra |
| Journey Medical Corporation | $19.93 | 2022 | |
| Kyowa Kirin, INC. | $19.52 | 2023 | Poteligeo |
| Prugen, INC. Pharmaceuticals | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.